The price tag marks a 107% premium over ArQule’s closing share price on Friday.
Burlington, Mass.-based ArQule focuses on therapies for treating cancer and rare diseases. The company’s lead investigational candidate, ARQ 531, is an inhibitor of an enzyme known as Bruton’s tyrosine kinase. ARQ 531 is in a Phase 2 dose expansion study to treat B-cell malignancies.
If you’re already a subscriber, log in to view this article here.